Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab

American Journal of Neuroradiology

Volumn 34, Issue 9, 2013, Pages 1752-1757

  Kothari, P D ^a   White, N S ^a,b   Farid, N ^a,b   Chung, R ^b   Kuperman, J M ^a,b   Girard, H M ^a   Shankaranarayanan, A ^a   Kesari, S ^a,c   McDonald, C R ^a,d   Dale, A M ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOMA; HUMAN; INTERMETHOD COMPARISON; MALE; RESTRICTION SPECTRUM IMAGING; TREATMENT RESPONSE; TUMOR GROWTH; WHITE MATTER;

ADULT; AGED; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85047687115     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3506     Document Type: Article

References (32)

1. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80
2. Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma. Nat Clin Pract Oncol 2008;5:634-44
3. Jain RK. Normalization of tumor vasculature: anemerging concept in antiangiogenic therapy. Science 2005;307:58-62
4. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978-85
5. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36
6. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-89
7. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imagingdetectspathologically confirmed, nonenhancing tumor progressioninapatient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28:e91-93
8. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010;96:423-31
9. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusionweighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60
10. Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am 2006;16:619-32, viii-ix
11. Castillo M, Smith JK, Kwock L, et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60-64
12. Stadnik TW, Chaskis C, Michotte A, et al. Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001;22:969-76
13. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
14. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with highgrade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60
15. White NS, Leergaard TB, D'Arceuil H, et al. Probing tissue microstructure with restriction spectrum imaging: histological and theoretical validation. Hum Brain Mapp 2013;34:327-46
16. White NS, McDonald CR, Farid N, et al. Improved conspicuity and delineationofhigh-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high b-value DWI and ADC. AJNR Am J Neuroradiol 2013;34:859-64
17. Holland D, Kuperman JM, Dale AM. Efficient correctionofinhomogeneous static magnetic field-induced distortioninecho planar imaging. Neuroimage 2010;50:175-83
18. McDonald CR, White NS, Farid N, et al. Recovery of white matter tracts in regions of peritumoral FLAIR hyperintensity with use of restriction spectrum imaging. AJNR Am J Neuroradiol 2013;34:1157-63
19. Holodny AI, Makeyev S, Beattie BJ, et al. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:1042-48
20. Gerstner ER, Chen PJ, Wen PY, et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010;12:466-72
21. Yamasaki F, Kurisu K, Satoh K, et al. Apparent diffusion coefficient of human brain tumors at MRimaging. Radiology 2005;235:985-91
22. Maier SE, Sun Y, Mulkern RV. Diffusion imaging of brain tumors. NMR Biomed 2010;23:849-64
23. Eis M, Els T, Hoehn-Berlage M. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 1995;34:835-44
24. Brunberg JA, Chenevert TL, McKeever PE, et al. In vivoMR determinationofwater diffusion coefficientsanddiffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 1995;16:361-71
25. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54
26. Rieger J, Bahr O, Muller K, et al. Bevacizumab-induced diffusionrestricted lesions in malignant glioma patients. J Neurooncol 2010;99:49-56
27. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012;72:402-07
28. Jovicich J, Czanner S, Greve D, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006;30:436-43
29. Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489-97
30. McDonald CR, Hagler DJ Jr, Girard HM, et al. Changes in fiber tract integrity and visual fields after anterior temporal lobectomy. Neurology 2010;75:1631-38
31. Holland D, McEvoy LK, Dale AM. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 2012;33:2586-602
32. Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusionrestricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 2012;33:1763-70